Navigation Links
Prosum Kicks Off Crowd Funding for Cancer Research
Date:8/9/2012

RENO, Nev., Aug. 9, 2012 /PRNewswire/ -- Prosum Breast Cancer Research, Inc. announces a Crowd Funding financing project to jump start its first research project to build the "You Will Be the Cure" for early detection breast health awareness and research. "Our first awareness project focuses on communicating individual experiences of women to educate all about the value with early detection starting at age 20," says Dave Wertzberger, Executive Director.

"We believe early detection education is much more than statistics and technology—women are the cure. The collective experience of survivors needs to be shared. We are convinced the profiles of women who have 'been there and done that' will provide invaluable awareness for women of all ages to advance the cure starting with early detection," adds Cindy Lain, Community Affairs Director.  "In addition, we see a number of early detection technologies coming to market and our goal is to confidentially involve volunteers with these technologies to improve device early detection usability and value," continues Wertzberger.

"Our Crowd Funding site at Rockethub.com provides one location to describe project goals and how individuals can support a new level of information for improving early detection and survival," says Wertzberger. "The Crowd Funding approach simplifies fund raising with contributions of $10, or more, while engaging folks wherever there is an Internet connection," says Wertzberger.

Prosum's awareness project will collect video histories as well as personal profiles in preparation for an updated web site for those who wish to share their stories to be part of our "You Will Be the Cure" awareness and research on early detection.  The fund raising goal is $30,000.  Any additional funds will be used to develop a confidential Breast Cancer History Database to improve early detection devices for positive change.

Press Ctrl, Click to follow the link Prosum Rocket Hub Link

About Prosum Breast Cancer Research

Prosum Research Foundation, Inc., dba Prosum Breast Cancer Research, (PBCR) is based in Reno, NV.  Founded in 2008, PBCR is a non-profit foundation dedicated to the dissemination of breast health information and education while advancing the state-of-the art of early detection of breast cancer to enhance current detection technologies to delivery early screening to more women by any physician.  www.prosumresearch.org 

For more information, contact: Dave Wertzberger, Executive Director 800-448-4981 dwertzberger@prosumresearch.org


'/>"/>
SOURCE Prosum Breast Cancer Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
2. RD Legal Funding Provides Immediate Settlement Financing to Growing Number of Yaz and Yasmin Plaintiffs
3. DePuy & Transvaginal Mesh Lawsuit Settlement Funding Leads Legal-Bay to Banner 2nd Quarter
4. BONESUPPORT Closes Second Tranche of Funding
5. Elsevier and Russias Skolkovo Foundation Sign Access Agreement to SciVerse Scopus and SciVal Funding
6. Igenica Closes $33 Million in Series C Funding
7. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
8. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
9. Independa Closes Convertible Note Funding at $2.35 Million
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):